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Abstract
BACKGROUND: Endometrial cancer (EC) is the fourth most common female cancer worldwide constituting 7% of 
cancer in women. It is a disease of older, postmenopausal women. The most of these patients have an identifiable 
source of excess estrogen, while in a small subset the pathogenesis is related to mismatch repair abnormality and 
lynch syndrome (LC). Mismatch repair behave as tumor suppressors and the most clinically relevant include MLH1, 
MSH2, MSH6, and PMS2. mutations in mismatch repair (MMR) results in a strong mutator phenotype known as 
microsatellite instability, which is a hallmark of LC-associated cancers. 
AIM: The aim of the study was to study microsatellite instability in endometrial cancer using the immunohistochemical 
expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2). 
MATERIAL AND METHODS: Sixty EC cases were studied using MLH-1, MSH-2, MSH-6, and PMS-2 
immunohistochemistry and their expression was correlated with different clinicopathologic parameters.
RESULTS: A statistically significant relationship exists between MMR immunohistochemistry (IHC) proteins and 
tumor grade. Intact MMR proteins profile was associated with the lower tumor grade (31.3% were Grade 1 and 
46.9% were Grade 2). Combined loss of MLH1/PMS2, combined loss of MSH2/MSH6, and isolated loss of PMS2 
were also associated with the lower tumor grade while isolated loss of MSH6 was associated with the high tumor 
grade. However, no statistically significant correlation was found between MMR IHC proteins expression and the age 
of patients; tumor histopathological types, or FIGO stage.
CONCLUSION: A statistically significant correlation between the tumor grade of EC cases and the MMR IHC 
proteins was found. Further studies are recommended to assess correlation between MMR proteins defect and 
different clinicopathological parameters of endometrial carcinoma.
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Introduction
Endometrial cancer (EC) is the fourth most 
common cancer in women (7% of cancers in women). 
In 2019, there were estimated 61,880 new cases of and 
12,160 deaths from EC [1]. EC is a disease of older, 
postmenopausal women and is uncommon in young 
women; 2% to 14% of endometrial carcinomas occur 
in women 40 years of age and younger. The most of 
these patients have an identifiable source of excess 
estrogen, while in a small subset the pathogenesis 
is related to mismatch repair abnormality and lynch 
syndrome (LC) [2].
In Egypt, primary malignant uterine 
neoplasms constituted 1.28% of total primary 
malignant neoplasms at National Cancer Institute 
and 22.83% of malignant neoplasms of female genital 
system. The primary malignant uterine neoplasms 
constituted 34.46% of all uterine lesions. The most 
common types were endometrioid adenocarcinoma 
(59.58%), followed by carcinosarcoma (10.71%); 
serous adenocarcinoma (7.9%); leiomyosarcoma 
(6.2%); endometrial stromal sarcoma (4.69 %); and 
choriocarcinoma (3.94%) [3].
Endometrial carcinomas are pathogenetically 
divisible into type 1 and type 2 tumors [4]. Type 1 
tumors (Grade 1 and 2 endometrioid carcinoma) are 
the most common ECs. They may arise from complex 
atypical hyperplasia and are linked to excess of 
estrogen stimulation. As they are usually diagnosed at 
early stages, they present a relatively good prognosis. 
Type 2 tumors are the least common endometrial 
tumors. They include Grade 3 endometrioid tumors 
as well as tumors of non-endometrioid histology, 
and develop from atrophic endometrium. Type 2 
tumors are less hormone sensitive. Since they are 
diagnosed in later stages, they are generally more 
aggressive [5].
Postmenopausal women with higher total 
concentrations of estrogens are at increased endometrial 
carcinoma risk as are women with polycystic ovary 
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syndrome or estrogen producing ovarian tumors, earlier 
age at menarche, later age at menopause, nulliparity, 
or obesity. A positive family history of endometrial 
carcinoma, LC or Cowden syndrome elevates the risk 
of endometrial carcinoma [4].
LS or hereditary non-polyposis colon cancer 
is an autosomal dominant inherited disease caused by 
germline mutations in mismatch repair (MMR) genes. 
MLH1, MSH2, MSH6, and PMS2 mutation in this 
syndrome account for approximately 37, 41, 13, and 
9%, respectively. It is important to establish a diagnosis 
for this syndrome because of the associated elevated 
lifetime risk of developing cancers such as colorectal 
and ECs [6].
Among ECs, 2–5% are likely to be associated 
with LC, in women either endometrial or colorectal 
carcinomas could be the presenting or sentinel 
cancer [7].
Since, LC confers a 14–54% risk of developing 
EC [7]. Thus, it is clinically relevant to identify LS 
women among EC patients to predict and prevents the 
development of other LS-associated cancers. It would 
also provide blood relatives an opportunity for genetic 
analysis and surveillance for LS-associated cancers. 
Each of the 4 MMR germline mutations leads to distinct 
molecular pathologies [8], and thus individuals carrying 
different mutations should not be regarded as suffering 
from the same disease. PMS2 germline mutation is 
associated with later onset, weaker family history, 
and a lower risk for cancer compared with other MMR 
germline mutations [9].
Clinical criteria to predict the likelihood of 
LC including Amsterdam, Bethesda, and Society of 
Gynecologic Oncology are not accurate and molecular 
testing of tumors is required to confirm or exclude 
LC [7].
Molecular screening of the tumors for 
the presence of MMR proteins in the nuclei using 
immunohistochemistry (IHC) is an alternative method 
of screening with sensitivity ranging between 86 and 
100% [10].
There is a growing drive for universal 
screening of colorectal cancer (CRC) patients for 
LS [11], [12], [13]. Indeed, the National Institute of 
Health and Care Excellence in the United Kingdom has 
recently introduced a LS screening pathway for all CRC 
patients, alongside numerous institutions in the United 
States [14]. LS screening pathways utilize tumor-
based testing IHC for MMR protein loss, microsatellite 
instability (MSI) testing or MLH1 (promoter methylation 
testing) to triage cases to undergo germline testing 
to identify a pathogenic variant in one of the MMR 
genes. Universal screening of EC patients for LS 
has been recommended by numerous experts and 
specialist societies [15]. Such practice has already 
been adopted in several cancer centers across the 
world [16], [17], [18].
Methods
Sixty cases of endometrial carcinoma 
covering different age groups were retrieved from 
the pathology department, Ahmed Maher Teaching 
Hospital, Cairo, Egypt, during the period from January 
2013 to December 2016. Demographic and clinical 
data of the patients were collected from the hospital 
files.
Five um thick sections were cut from formalin-
fixed paraffin embedded tissue blocks and stained with 
hematoxylin and eosin for routine histopathological 
examination and determination of tumor type, grade, 
and stage.
Immunohistochemical staining was performed 
using immunostainer (Shandon Sequenza) using the 
labeled streptavidin biotin method with the following 
reagents: Diva Decloaker, pre-treatment antigen – 
retrieval, (Biocare Medical Catalog number: DV2004 
LX, MX), hydrogen peroxide block (Lab vision, 
USA, Catalog number: TA-060-HP), and Ultravision 
large volume detection system (Lab vision, USA, 
Catalog number: TP-060- HL) including Ultra V 
block, biotinylated goat anti-polyvalent plus (link) and 
streptavidin peroxidase plus (label), and DAB plus 
substrate system (Lab vision, USA, Catalog number: 
TA-060-HDX) including DAB plus chromogen and DAB 
plus substrate. The primary antibodies were PMS-2: A 
mouse polyclonal antibody (Biocare Medical Catalog 
number: PM 344 AA), MLH-1: A mouse monoclonal 
antibody (Biocare Medical Catalog number: PM 220 
AA), MSH-6: A mouse monoclonal antibody (Biocare 
Medical Catalog number: PM 265 AA), and MSH-2: A 
mouse monoclonal antibody (Biocare Medical Catalog 
number: PM 219 AA).
Lymphocytes and/or stroma were used as 
internal positive controls [9], [19]. Sections of the same 
tissue were used following the same procedure with 
PBS used instead of the primary antibody as internal 
negative controls.
Complete absence of nuclear staining in 
the tumor cells is interpreted as loss of MMR protein 
expression [9], [20].
The presence of nuclear staining in tumor 
cells is good evidence of retained MMR protein, even 
if it is focal and weak staining. This has led to neglect 
staining pattern interpretation, with the exception 
of cases that show complete absence of nuclear 
staining [9].
Statistical analyses were performed using 
Statistical Package for the Social Science (SPSS 
17.0 for windows; SPSS Inc, Chicago, IL, 2010). Chi-
Square test was used to examine the relationship 
between two qualitative variables and between 
one quantitative and one qualitative variable. p is 
significant when ≤ 0.05.
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Results
Patient’s ages ranged between 37 and 75 
years with a mean age of 60.03 ± 9.244 years and 
median age is 60.8 years.
The most of the cases were endometrioid 
adenocarcinomas (80%) including conventional 
endometrioid carcinoma (66.7%), endometrioid with 
squamoid differentiation (8.3%), and endometrioid 
villoglandular subtype (5%). Twenty percent were 
non-endometrioid including serous carcinoma (5%), 
carcinosarcoma (5%), and mixed carcinoma (10%). 
The majority of tumors were Grade II (40 %). About 
95.8% of tumors were FIGO Stage I.
Figure 1: Endometrioid adenocarcinoma, Grade II, intact mutations in 
mismatch repair immunohistochemistry proteins, (a): MLH1 positive 
(×200), (b): PMS2 positive (×200), (c): MSH2 positive (×200), 
(d): MSH6 positive (×200)
a
c
b
d
Both MLH1/PMS2 were lost in 10% of cases 
and both MSH2/MSH6 were lost in 3.3% of cases, while 
all MMR proteins were lost in 15% of cases. Isolated 
PMS2 loss was found in 15.0% of cases and isolated 
MSH6 loss was found in 3.3% of cases. MMR proteins 
were intact in 53.3% of cases.
There was statistically significant correlation 
between MMR IHC expression and tumor grade 
(p = 0.028). Intact MMR proteins profile was associated 
with the lower tumor grade (31.3% were Grade 1 and 
46.9% were Grade 2) (Figure 1). Combined loss of 
MLH1/PMS2, combined loss of MSH2/MSH6 (Figure 
2) and isolated loss of PMS2 were also associated 
with the lower tumor grade while isolated loss of MSH6 
was associated with high tumor grade (Figure 3) 
(Table 1).
No statistically significant correlation could be 
found between MMR proteins expression and age of 
the patients, tumor types, or FIGO stage.
Discussion
EC is the most common gynecological 
malignancy in high‐income countries [5].
Mismatch repair proteins behave as tumor 
suppressors [17]. MMR loss results in a strong mutator 
phenotype known as MSI, which is a hallmark of 
LC-associated cancers [21].
Figure 2: Endometrioid adenocarcinoma, Grade II, mutations in 
mismatch repair immunohistochemistry proteins, loss of MSH2 
and MSH6, (a): MLH1 positive (×200), (b): PMS2 positive (×200), 
(c): MSH2 negative (×200), (d): MSH6 negative (×200)
a
c d
b
Concerning the immunohistochemical 
expression of MMR proteins in endometrial carcinoma 
cases, all MMR proteins were intact in (53.3%) of cases, 
MLH1/PMS2 loss was in (10%) of cases, isolated PMS2 
loss was in (15%) of cases, MSH2/MSH6 loss was in
Figure 3: Serous endometrial adenocarcinoma, Grade III, FIGO Stage 
IB, isolated MSH6 loss, (a): MLH1 positive (×200), (b): PMS2 positive 
(×200), (c): MSH2 positive (×200), (d): MSH6 negative (×200).
a b
dc
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(3.3%) of cases, isolated loss of MSH6 was in 3.3% 
of cases, and all MMR proteins were lost in (15%) of 
cases. These results are near to those obtained by 
Egoavil et al. [22], Buchanan et al. [23], Ferguson 
et al. [24], Joehlin-Price et al. [25], and Dudley 
et al. [20].
Table 1: Relationship between MMR IHC expression and the 
tumor grades of EC cases
IHC panel Grade I Grade II Grade III
Count 
(% within IHC panel)
Count 
(% within IHC panel)
Count 
(% within IHC panel)
No loss 10 (31.3) 15 (46.9) 7 (21.9)
MLH1/PMS2 loss 1 (16.7) 5 (83.3) 0 (0)
PMS2 loss 6 (66.7) 1 (11.1) 2 (22.2)
MSH2/MSH6 loss 2 (100) 0 (0) 0 (0)
MSH6 loss 0 (0) 0 (0) 2 (100)
All loss 3 (33.3) 3 (33.3) 3 (33.3)
Total 22 (100) 24 (100) 14 (100)
Sig. (p) 0.028
MMR: Mutations in mismatch repair, EC: Endometrial cancer, IHC: Immunohistochemistry.
There was statistically significant correlation 
between MMR IHC expression and tumor grade. 
This agreed with Clarke and Cooper [26] who found 
significant correlation between tumor grades and 
MMR IHC expression (p = 0.0001) and (p = 0.009). 
respectively. Moreover. Hirasawa et al. [27] found that 
MSI high (MSI-H) was significantly correlated with high 
grade tumors (Grade 3 vs. Grades 1 and 2).
There was no statistically significant correlation 
between the patient’s age of EC cases and MMR 
proteins expression. This was in agreement with the 
previous study of Mas-Moya et al. [28] but in contrast 
to Egoavil et al. [22] who found significant correlation 
between patient’s age and MMR IHC expression and/
or MSI testing that the suspected hereditary condition 
was more frequently found in women younger than 50 
years.
There was no statistically significant 
correlation between the histopathological types of 
endometrial carcinoma and MMR IHC expression 
which was in agreement with the study of Egoavil 
et al. [22], Joehlin-Price et al. [25], and Mas-Moya 
et al. [28].
There was no statistically significant correlation 
between the FIGO stage of endometrial carcinoma (EC) 
cases and MMR IHC expression the same as Joehlin-
Price et al. [25] study.
MMR-IHC can be performed as part of a 
routine surgical pathology workflow, and validation is 
achievable for virtually any laboratory that processes 
IHC [19]. It can be used to evaluate MMR proteins 
expression and select patients for genetic testing. Loss 
or abnormal protein expression may be suggestive of 
LS [29].
In addition to influencing health-care 
decisions for individual cancer patients, a diagnosis 
of LS affects screening strategies for related family 
members. Involvement of genetic counselors is 
critical for advising both individual cancer patients 
and family members about the implications of 
testing [30].
Conclusion
There is a statistically significant correlation 
between the tumor grade of EC cases and the MMR IHC 
proteins expression and no correlation with the other 
analyzed clinicopathological parameters in this study. 
Hence, further studies on MMR proteins expression are 
recommended.
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